# Galvanize Therapeutics

> US medical-device company commercializing pulsed electric field instruments for soft-tissue ablation, while investigating chronic-lung and oncology applications.

## Why it is interesting

Galvanize announced a CLOSED $130M Series D on November 16, 2026, led by HealthQuest Capital. Unlike a purely preclinical biotech, its Aliya system is marketed under FDA soft-tissue-ablation 510(k) clearances. The disease-specific benefit and immune-effect hypotheses should not be confused with that clearance. The issuer reports over 4,000 procedures and over 300 PROPEL-registry enrollments, not 4,000 controlled-trial successes.

## Profile

- **Latest funding:** Series D — $130M (November 16, 2026)
- **Latest known valuation:** Not publicly disclosed
- **Total disclosed equity funding:** $330M
- **Stage:** growth
- **Status:** private
- **Industries:** N/A
- **Coverage:** full
- **Last updated:** 2026-11-16
- **Latest funding investors:** HealthQuest Capital, Olympus Innovation Ventures, Braidwell LP, Sofinnova Partners, Norwest

## Key facts

- Closed $130M Series D announced 2026-11-16, led by HealthQuest Capital, with Olympus Innovation Ventures and Braidwell as new investors.
- Earlier original-company releases disclose $100M Series B (September 2022) and $100M Series C (September 2025). Three documented rounds total $330M; undisclosed earlier funding is excluded.
- Issuer reports over 4,000 Aliya procedures and more than 300 enrolled in PROPEL registry; counts are not efficacy endpoints or audited sales.
- FDA 510(k) K253826 cleared Aliya EX May 7, 2026 for surgical ablation of soft tissue, not for treatment/cure of a specified disease.
- Immune activation and disease-specific oncology benefit remain investigational; patient-benefit effectiveness has not been established.

## Funding history

- Series D · $130M · November 16, 2026
  Source: https://www.prnewswire.com/news-releases/galvanize-therapeutics-raises-130-million-in-oversubscribed-series-d-financing-to-accelerate-commercial-growth-and-advance-pef-innovation-302939618.html
- Series C · $100M · September 3, 2025
  Source: https://www.prnewswire.com/news-releases/galvanize-therapeutics-raises-100-million-in-oversubscribed-series-c-financing-to-transform-the-treatment-of-cancer-and-chronic-lung-disease-302544329.html
- Series B · $100M · September 15, 2022
  Source: https://www.prnewswire.com/news-releases/galvanize-therapeutics-announces-merger-to-create-the-premier-pulsed-electric-field-therapy-company-and-completion-of-100-million-series-b-financing-301624935.html

**By:** [Venture Capital Tracker](https://venturecapitaltracker.com/editorial-policy)
**Last updated:** November 16, 2026

**Editorial note:** AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.

---
Source: https://venturecapitaltracker.com/startup/galvanize-therapeutics
